We’re invested in health to develop the next generation of medical innovations.

From early-stage seed investment through to expansion capital, we support life science companies from proof-of-concept through to commercialisation.

Ground breaking medical innovation, better patient outcomes, strong financial returns.

Brandon has been effective in raising successive funds that collectively cover the spectrum of life science venture investing. We also have a co-investment arrangement with our investors, providing significant capacity to support our advancing portfolio companies.

active portfolio companies

Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom

Investment
Portfolio

Recognising the effort required to commercialise a great idea, we partner with entrepreneurs for the long-haul, working collaboratively with them to support the development and commercialisation of their technology, thereby creating value for their teams, our investors and ultimately benefiting patients.

We like to invest early - we have been the founding investor for most of our current portfolio companies

Ankere Therapeutics

Developing novel therapeutics for inflammatory diseases

Amaroq Therapeutics

Targeting long non-coding RNAs for next generation cancer therapies
Pathios Therapeutics

Delivering groundbreaking therapies for autoimmune diseases & cancer.

George Medicines

George Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)
Glyscend

Harnessing the power of bariatric surgery in Type 2 diabetes treatment with a non-absorbable polymer
Myricx Pharma

Unlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
Allay Therapeutics

Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
Currus Biologics

Developing the next generation of CAR-T cell therapies to treat solid cancers
See our investment portfolio

News

View all posts

Contact Us

Melbourne

Level 9, 31 Queen Street

Melbourne VIC 3000

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

Sydney

Suite 2.05, 1 York Street

Sydney NSW 2000

Phone +61 2 8227 7080

Email: info@brandoncapital.com.au

San Francisco

Brandon Capital LLC

1 Letterman Dr, Suite C3-300

San Francisco, CA 94129

Phone +61 3 9657 0700

Email: info@brandoncapital.com.au

London

7 Pancras Square

Kings Cross, London N1C 4AG

United Kingdom

Email: info@brandoncapital.com.au

For media inquiries, contact

Damon Birrell

db@manacommunications.com

+61 412 970 870


Caleb Hulme-Moir

chm@manacommunications.com

+64 20 698 065

© Copyright 2022 Brandon Capital Partners